Boston Scientific Cardiology

Boston Scientific has closed on an agreement with Elutia, Inc. to acquire the company’s bioenvelope assets, including the antibiotic-eluting EluPro™ BioEnvelope and the CanGaroo® BioEnvelope, designed to prevent certain post-operative complications for devices such as pacemakers and defibrillators. The addition of these devices to our portfolio will allow us to broaden their availability, providing a bioenvelope option for more physicians and their patients.

📢 We are pleased to announce that Boston Scientific has entered into a definitive agreement with Elutia to acquire the EluPro™ BioEnvelope and the CanGaroo® Envelope. These products are designed to help prevent certain post-operative complications associated with implantable cardiac devices such as pacemakers and defibrillators. These advancements will further strengthen our ability to protect patients with these devices, and we look forward to equipping more physicians with technologies designed to improve clinical outcomes. https://lnkd.in/eeZ4y7sC

Join us for the 8th edition of Left Main Bifurcation Conclave in collaboration with EUROPEAN BIFURCATION CLUB .. !

Review study highlights to learn how the VersaCross™ RF Wire achieved 100% transseptal puncture success with lower energy and reduced risk of septum and device damage compared to an electrified guidewire: https://bit.ly/46iugz9 VersaCross™ Access Solution Indications, Safety, and Warnings: https://qrco.de/bs-vxs

🚀 Exciting News in Cardiac Care! 🚀 We're thrilled to announce the successful completion of the first wave of procedures using our revolutionary VersaCross Connect™ products! Our cutting-edge technology enables a zero exchange transseptal workflow, simplifying left heart access procedures and enhancing efficiency for clinicians. A big thank you to the pioneering teams who are leading the way in transforming cardiac care with this innovation: • Dr Joaquin Osca and his team at Hospital La Fe, Spain • Dr Dr. med. Sebastian Maximilian Haberkorn, M.Sc. and his team at University Hospital Frankfurt, Germany • Prof. Amir Jadidi, Dr Stefanie Hess and Mrs Michaela Graf from LUKS Spitalbetriebe, Switzerland Together, we're making strides towards better patient outcomes and procedural excellence. #BSCEMEA #MedicalInnovation #MedTech #HealthcareExcellence #CardiacCare

We’ve officially completed the acquisition of SoniVie Ltd, bringing an innovative ultrasound-based technology for renal artery denervation into our interventional cardiology portfolio to support the treatment of hypertension. Following regulatory approval, we believe this treatment option can serve as an important step forward in shaping the future of hypertension care.

Protect your patients from embolic debris with SENTINEL, the only stroke protection solution that seamlessly integrates into your workflow. With a median deployment time of just 4 minutes, you can focus on what truly matters: patient care. Learn more: https://bit.ly/4hUiTzn Safety info: https://bit.ly/4c2Ns4q

We’re pleased to announce that we’ve entered into a definitive agreement to acquire SoniVie, developer of an intravascular ultrasound system designed to denervate the nerves surrounding blood vessels to treat a variety of hypertensive disorders – including renal artery denervation for hypertension. The differentiated TIVUSTM Intravascular Ultrasound System aims to reduce activity in the kidney’s renal nerves and serve as an alternative or adjunctive therapy to antihypertensive medications to help regulate blood pressure. https://bit.ly/3DbxDf1

The first-ever FARAFLEX™ Mapping and Pulsed Field Ablation (PFA) Catheter cases were completed at KBC Split in Split, Croatia, as part of the premarket ELEVATE-PF feasibility study, performed by Dr. Ante Anic and observed by Drs. Oussama Wazni and Walid Saliba. Our innovation and clinical investment in FARAFLEX™ continue to position Boston Scientific as a leader in #PFA to further the treatment of cardiac arrhythmias. FARAFLEX™ is designed to optimize mapping and ablation in a single catheter with a wide-area tip and high-fidelity sensing electrodes. The 8 Fr NAV-enabled catheter will be integrated into the OPAL HDx™ Mapping System enabling precise diagnostic mapping to understand arrhythmia mechanism and target ablations accordingly. This case video visualizes the use of FIELDTAG™ Technology PFA markers to plan, execute, and confirm PFA delivery via the FARAFLEX™ Catheter. Tune in for a deeper discussion on FARAFLEX™ at #HRS2025 in San Diego, CA on April 26th @ 12:00pm PDT at the “Transforming AF Treatment: Innovations to the FARAPULSE™ Portfolio” Rhythm Theater. Learn more about FARAPULSE™ Pulsed Field Ablation System: https://bit.ly/4hXU3zp #EPeeps #PFA FARAFLEX™ is pending CE Mark and FDA approval. Not available for sale.